Akttyva Therapeutics, with a valuation of $10 million, is testing the waters on Fundify. It is a biotechnology company working on developing a cure for Acute Respiratory Distress Syndrome (ARDS). ARDS is the common cause of death in pneumonia, flu, and COVID-19; thus, by finding the cure for ARDS, Akttyva Therapeutics aims to convert COVID-19 to the common cold. The first product of Akttyva Therapeutics, AKT-001, is in human safety Phase 1 trial and is patent protected. Katya Tsaioun and Lana Gladstein founded Akttyva Therapeutics in October 2020. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1,000,000. The campaign proceeds will be used for clinical trials.